Canada· CA-DIN-02475774
JULUCA
A dolutegravir and rilpivirine product containing dolutegravir (dolutegravir sodium) + rilpivirine (rilpivirine hydrochloride), registered in Canada by VIIV HEALTHCARE ULC. The same ATC class is registered in 13 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Dolutegravir and rilpivirine is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR21 (dolutegravir and rilpivirine), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Dolutegravir and rilpivirine · ATC J05AR21
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) + RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE)
- Manufacturer
- VIIV HEALTHCARE ULC
- Country
- Canada (CA)
- ATC code
- J05AR21
- ATC class
- Dolutegravir and rilpivirine
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dolutegravir and rilpivirine in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandJulucaParanova Oy
- CzechiaJULUCAViiV Healthcare BV, Amersfoort
- United StatesJulucaViiV Healthcare Company
- United KingdomJuluca 50mg/25mg tabletsViiV Healthcare UK Ltd
- SwitzerlandJuluca
- NetherlandsJuluca 50 mg/25 mg, filmomhulde tablettenViiV healthcare B.V.
- NorwayJulucaViiV Healthcare BV (1)
- PolandJulucaViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Juluca
- Liechtenstein · Juluca
- Norway · Juluca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2a76bb99-0aaf-40d0-9c05-ae2a03e39f5d GET /v1/drugs/2a76bb99-0aaf-40d0-9c05-ae2a03e39f5d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02475774",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "J05AR21",
"schedule": [
"Prescription"
],
"drug_code": "96645",
"strengths": [
"50 MG",
"25 MG"
],
"ahfs_class": null,
"substances": [
"DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)",
"RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE)"
],
"product_categorization": null
}See everything about dolutegravir and rilpivirine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.